Assertio (ASRT) Revenue & Revenue Breakdown
Assertio Revenue Highlights
Latest Revenue (Y)
$152.07M
Latest Revenue (Q)
$32.45M
Main Segment (Y)
Product
Main Geography (Y)
CANADA
Assertio Revenue by Period
Assertio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $152.07M | -2.67% |
| 2022-12-31 | $156.23M | 40.73% |
| 2021-12-31 | $111.01M | 4.46% |
| 2020-12-31 | $106.28M | -53.69% |
| 2019-12-31 | $229.50M | -26.39% |
| 2018-12-31 | $311.77M | -18.11% |
| 2017-12-31 | $380.72M | -16.49% |
| 2016-12-31 | $455.90M | 33.02% |
| 2015-12-31 | $342.74M | -12.20% |
| 2014-12-31 | $390.36M | 190.87% |
| 2013-12-31 | $134.21M | 47.78% |
| 2012-12-31 | $90.82M | -31.70% |
| 2011-12-31 | $132.97M | 64.64% |
| 2010-12-31 | $80.76M | 39.90% |
| 2009-12-31 | $57.73M | 65.69% |
| 2008-12-31 | $34.84M | -46.87% |
| 2007-12-31 | $65.58M | 586.63% |
| 2006-12-31 | $9.55M | 116.81% |
| 2005-12-31 | $4.41M | 2074.73% |
| 2004-12-31 | $202.57K | -79.37% |
| 2003-12-31 | $981.99K | -40.89% |
| 2002-12-31 | $1.66M | -54.78% |
| 2001-12-31 | $3.67M | 106.81% |
| 2000-12-31 | $1.78M | 1440.16% |
| 1999-12-31 | $115.33K | -85.58% |
| 1998-12-31 | $800.00K | 33.33% |
| 1997-12-31 | $600.00K | 100.00% |
| 1996-12-31 | $300.00K | - |
Assertio generated $152.07M in revenue during NA 2023, up -2.67% compared to the previous quarter, and up 48.78% compared to the same period a year ago.
Assertio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $32.45M | -1.63% |
| 2023-12-31 | $32.98M | -7.42% |
| 2023-09-30 | $35.63M | -13.09% |
| 2023-06-30 | $40.99M | -3.47% |
| 2023-03-31 | $42.47M | -15.66% |
| 2022-12-31 | $50.35M | 47.18% |
| 2022-09-30 | $34.21M | -2.62% |
| 2022-06-30 | $35.13M | -3.85% |
| 2022-03-31 | $36.54M | 9.62% |
| 2021-12-31 | $33.33M | 30.85% |
| 2021-09-30 | $25.47M | 0.39% |
| 2021-06-30 | $25.37M | -5.46% |
| 2021-03-31 | $26.84M | -11.06% |
| 2020-12-31 | $30.18M | -12.70% |
| 2020-09-30 | $34.56M | 67.65% |
| 2020-06-30 | $20.62M | -1.43% |
| 2020-03-31 | $20.92M | -64.68% |
| 2019-12-31 | $59.23M | 7.40% |
| 2019-09-30 | $55.15M | -3.59% |
| 2019-06-30 | $57.20M | -1.25% |
| 2019-03-31 | $57.93M | 35.99% |
| 2018-12-31 | $42.60M | -45.03% |
| 2018-09-30 | $77.49M | 22.47% |
| 2018-06-30 | $63.27M | -50.72% |
| 2018-03-31 | $128.40M | 36.01% |
| 2017-12-31 | $94.41M | -1.05% |
| 2017-09-30 | $95.41M | -5.02% |
| 2017-06-30 | $100.46M | 11.07% |
| 2017-03-31 | $90.45M | -27.01% |
| 2016-12-31 | $123.91M | 12.11% |
| 2016-09-30 | $110.52M | -5.28% |
| 2016-06-30 | $116.68M | 11.36% |
| 2016-03-31 | $104.78M | -5.75% |
| 2015-12-31 | $111.17M | 6.02% |
| 2015-09-30 | $104.86M | 10.95% |
| 2015-06-30 | $94.50M | 193.46% |
| 2015-03-31 | $32.20M | -83.45% |
| 2014-12-31 | $194.60M | 277.98% |
| 2014-09-30 | $51.48M | -23.99% |
| 2014-06-30 | $67.73M | -11.51% |
| 2014-03-31 | $76.54M | 88.49% |
| 2013-12-31 | $40.61M | 8.41% |
| 2013-09-30 | $37.46M | 25.02% |
| 2013-06-30 | $29.96M | 14.48% |
| 2013-03-31 | $26.17M | -1.56% |
| 2012-12-31 | $26.59M | -20.11% |
| 2012-09-30 | $33.28M | 135.88% |
| 2012-06-30 | $14.11M | -16.19% |
| 2012-03-31 | $16.84M | 38.77% |
| 2011-12-31 | $12.13M | -26.57% |
| 2011-09-30 | $16.52M | -22.13% |
| 2011-06-30 | $21.22M | -74.47% |
| 2011-03-31 | $83.10M | 298.39% |
| 2010-12-31 | $20.86M | 3.64% |
| 2010-09-30 | $20.13M | -17.58% |
| 2010-06-30 | $24.42M | 58.98% |
| 2010-03-31 | $15.36M | 16.06% |
| 2009-12-31 | $13.23M | -42.50% |
| 2009-09-30 | $23.01M | 98.26% |
| 2009-06-30 | $11.61M | 17.59% |
| 2009-03-31 | $9.87M | 13.28% |
| 2008-12-31 | $8.71M | -38.24% |
| 2008-09-30 | $14.11M | 123.45% |
| 2008-06-30 | $6.32M | 10.77% |
| 2008-03-31 | $5.70M | 7.87% |
| 2007-12-31 | $5.29M | - |
Assertio generated $32.45M in revenue during Q1 2024, up -1.63% compared to the previous quarter, and up 64.44% compared to the same period a year ago.
Assertio Revenue Breakdown
Assertio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| C A M B I A | $24.72M | $24.97M | $28.35M |
| Other Revenue | $-1.29M | $-985.00K | - |
| Zipsor | $3.36M | $10.19M | $13.29M |
| SPRIX Nasal Spray | $9.11M | $8.68M | $11.08M |
| Royalties And Milestones | $2.40M | $2.58M | $1.52M |
| Product, Other | $4.67M | $5.03M | - |
| Product | $155.12M | $109.42M | $93.50M |
| Otrexup | $11.15M | - | - |
| INDOCIN Products | $100.34M | $60.56M | $31.68M |
| Commercialization Agreement | - | - | $11.26M |
| Product and Service, Other | - | $-985.00K | $9.10M |
Assertio's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (50.11%), INDOCIN Products (32.41%), C A M B I A (7.98%), Otrexup (3.60%), SPRIX Nasal Spray (2.94%), Product, Other (1.51%), Zipsor (1.09%), Royalties And Milestones (0.78%), and Other Revenue (-0.42%).
Quarterly Revenue by Product
| Product/Service | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDOCIN Products | $17.95M | $28.07M | $30.35M | $34.27M | $21.87M | $21.36M | $18.34M | $13.07M | $14.60M | $12.48M | $13.77M | $5.43M | - | - |
| Zipsor | $597.00K | $1.00M | $1.15M | $660.00K | $259.00K | $2.23M | $3.38M | $2.58M | $2.22M | $4.03M | $3.40M | $3.54M | - | - |
| Product | $35.14M | $40.08M | $41.77M | $49.86M | $34.28M | $35.43M | $35.55M | $32.15M | $26.00M | $24.83M | $26.41M | $29.82M | $34.27M | $20.16M |
| Product, Other | $12.00K | $605.00K | $796.00K | $786.00K | $884.00K | $1.64M | $1.31M | - | - | - | - | - | - | - |
| CAMBIA | $1.99M | $1.80M | $2.26M | $5.81M | $5.47M | $6.13M | $6.46M | $7.45M | - | - | - | - | - | - |
| Otrexup Acquisition | $2.81M | $3.59M | $2.82M | $3.00M | $3.08M | - | - | - | - | - | - | - | - | - |
| Product and Service, Other | - | $185.00K | $-540.00K | $-750.00K | - | $-9.00K | $-941.00K | $105.00K | $1.43M | $2.63M | $4.01M | - | - | - |
| Royalties And Milestones | $490.00K | $723.00K | $697.00K | $487.00K | $473.00K | $451.00K | $992.00K | $1.19M | $416.00K | $542.00K | $434.00K | $361.00K | $299.00K | $452.00K |
| SPRIX Nasal Spray | $2.54M | $2.37M | $1.89M | $2.67M | $2.46M | $1.77M | $1.76M | $2.94M | $1.70M | $3.83M | $5.64M | $1.60M | - | - |
| C A M B I A | - | - | - | $7.26M | $7.34M | $6.85M | $7.78M | - | - | - | - | - | - | - |
| Commercialization Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Commercialization Rights And Facilitation Services | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| OXAYDO | - | - | - | - | - | - | - | - | - | - | - | - | - | $517.00K |
| Janssen Nucynta | - | - | - | - | - | - | - | - | - | - | - | - | - | $577.00K |
| Gralise | - | - | - | - | - | - | - | - | - | - | - | - | - | $-116.00K |
| SOLUMATRIX Products | - | - | - | - | - | - | - | - | - | - | - | - | - | $836.00K |
Assertio's latest quarterly revenue breakdown by segment (product or service), as of Sep 23: Product (57.11%), INDOCIN Products (29.17%), Otrexup Acquisition (4.56%), SPRIX Nasal Spray (4.14%), CAMBIA (3.24%), Zipsor (0.97%), Royalties And Milestones (0.80%), and Product, Other (0.02%).
Assertio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| CANADA | $1.90M | $2.50M | $1.50M |
Assertio's latest annual revenue breakdown by geography, as of Dec 22: CANADA (100.00%).
Quarterly Revenue by Country
| Country | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|
| CANADA | $500.00K | $400.00K | $500.00K | $400.00K | $500.00K | $500.00K | $500.00K | $300.00K | $300.00K |
Assertio's latest quarterly revenue breakdown by geography, as of Sep 23: CANADA (100.00%).
Assertio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| CTLT | Catalent | $4.38B | $1.07B |
| AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| EOLS | Evolus | $199.72M | $66.22M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| ASRT | Assertio | $152.07M | $31.13M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
| ALVO | Alvotech | $91.43M | $12.43M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| ACRX | Talphera | $651.00K | $117.00K |
ASRT Revenue FAQ
What is Assertio’s yearly revenue?
Assertio's yearly revenue for 2023 was $152.07M, representing a decrease of -2.67% compared to 2022. The company's yearly revenue for 2022 was $156.23M, representing an increase of 40.73% compared to 2021. ASRT's yearly revenue for 2021 was $111.01M, representing an increase of 4.46% compared to 2020.
What is Assertio’s quarterly revenue?
Assertio's quarterly revenue for Q1 2024 was $32.45M, a -1.63% decrease from the previous quarter (Q4 2023), and a -23.59% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $32.98M, a -7.42% decrease from the previous quarter (Q3 2023), and a -34.49% decrease year-over-year (Q4 2022). ASRT's quarterly revenue for Q3 2023 was $35.63M, a -13.09% decrease from the previous quarter (Q2 2023), and a 4.14% increase year-over-year (Q3 2022).
What is Assertio’s revenue growth rate?
Assertio's revenue growth rate for the last 3 years (2021-2023) was 36.98%, and for the last 5 years (2019-2023) was -33.74%.
What are Assertio’s revenue streams?
Assertio's revenue streams in c 22 are C A M B I A, Other Revenue, Zipsor, SPRIX Nasal Spray, Royalties And Milestones, Product, Other, Product, Otrexup, and INDOCIN Products. C A M B I A generated $24.72M in revenue, accounting 7.98% of the company's total revenue, down -1.01% year-over-year. Other Revenue generated $-1.29M in revenue, accounting -0.42% of the company's total revenue, up 30.96% year-over-year. Zipsor generated $3.36M in revenue, accounting 1.09% of the company's total revenue, down -66.97% year-over-year. SPRIX Nasal Spray generated $9.11M in revenue, accounting 2.94% of the company's total revenue, up 5.00% year-over-year. Royalties And Milestones generated $2.4M in revenue, accounting 0.78% of the company's total revenue, down -6.82% year-over-year. Product, Other generated $4.67M in revenue, accounting 1.51% of the company's total revenue, down -7.10% year-over-year. Product generated $155.12M in revenue, accounting 50.11% of the company's total revenue, up 41.77% year-over-year. Otrexup generated $11.15M in revenue, accounting 3.60% of the company's total revenue INDOCIN Products generated $100.34M in revenue, accounting 32.41% of the company's total revenue, up 65.69% year-over-year.
What is Assertio’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Assertio was Product. This segment made a revenue of $155.12M, representing 50.11% of the company's total revenue.